Cypher clarification
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson/Cordis' Cypher drug-eluting coronary stent uses sirolimus (Rapamune), licensed from Wyeth and bound to the stent using SurModics' coating technology and related reagents. "The Gray Sheet" had incorrectly stated that the Cypher uses paclitaxel (1"The Gray Sheet" Jan. 6, 2003, p. 3)...
You may also be interested in...
Guidant Shifts To Everolimus As Stents Developed With Cook Under-Achieve
Guidant will pursue development of two polymer-coated everolimus-eluting stent platforms in the wake of disappointing study results with its Achieve non-polymer paclitaxel-eluting stent
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.